InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Ensysce Biosciences, Inc.

ENSC Clue Score53
United States Fiscal year ends December CIK 0001716947
$0.53 +15.07% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.53 −77.57% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 26 Feb 2018. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2018Operating income−1.0Net income2.1Fiscal year 2019Operating income−3.3Net income−1.1 −150.3%Fiscal year 2020Revenue3.9Operating income−1.6Net income4.3EPS, diluted0.00Fiscal year 2021Revenue3.5 −10.2%Operating income−19.9Net income−29.1 −776.1%EPS, diluted−1.48Fiscal year 2022Revenue2.5 −28.5%Operating income−24.2Net income−24.2EPS, diluted−139.42Fiscal year 2023Revenue2.2 −11.6%Operating income−10.7Net income−10.6EPS, diluted−70.40Fiscal year 2024Revenue5.2 +133.6%Operating income−6.7Net income−8.0EPS, diluted−11.45Fiscal year 2025Revenue5.1 −2.8%Operating income−10.2Net income−10.2EPS, diluted−3.98
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a 3.9 3.5 2.5 2.2 5.2 5.1
Growth −10.2% −28.5% −11.6% +133.6% −2.8%
Operating income −1.0 −3.3 −1.6 −19.9 −24.2 −10.7 −6.7 −10.2
Net income 2.1 −1.1 4.3 −29.1 −24.2 −10.6 −8.0 −10.2
Growth −150.3% −776.1%
EPS, diluted n/a n/a 0.00 −1.48 −139.42 −70.40 −11.45 −3.98

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2018Fiscal year 2019Fiscal year 2020Operating margin−41.0%Net margin109.7%Fiscal year 2021Operating margin−562.7%Net margin−825.4%Fiscal year 2022Operating margin−959.9%Net margin−959.3%Fiscal year 2023Operating margin−480.5%Net margin−476.4%Fiscal year 2024Operating margin−129.2%Net margin−153.3%Fiscal year 2025Operating margin−202.1%Net margin−200.8%Free cash flow margin−156.5%
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a −41.0% −562.7% −959.9% −480.5% −129.2% −202.1%
Net margin n/a n/a 109.7% −825.4% −959.3% −476.4% −153.3% −200.8%
Free cash flow margin n/a n/a n/a n/a n/a n/a n/a −156.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2018Operating cash flow−1.2Fiscal year 2019Operating cash flow−1.4Buybacks−11.6Fiscal year 2020Operating cash flow−1.2Buybacks−184.8Fiscal year 2021Operating cash flow−8.2Fiscal year 2022Operating cash flow−17.9Fiscal year 2023Operating cash flow−10.8Fiscal year 2024Operating cash flow−7.5Fiscal year 2025Operating cash flow−7.8Capital expenditure−0.1Free cash flow−7.9
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −1.2 −1.4 −1.2 −8.2 −17.9 −10.8 −7.5 −7.8
Capital expenditure n/a n/a n/a n/a n/a n/a n/a −0.1
Free cash flow n/a n/a n/a n/a n/a n/a n/a −7.9
Growth
Buybacks n/a −11.6 −184.8 n/a n/a n/a n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2018Shareholders’ equity5.0Fiscal year 2019Shareholders’ equity5.0Fiscal year 2020Cash0.2Shareholders’ equity−6.4Fiscal year 2021Cash12.3Shareholders’ equity−7.9Fiscal year 2022Cash3.1Shareholders’ equity−3.7Fiscal year 2023Cash1.1Shareholders’ equity−0.3Fiscal year 2024Cash3.5Shareholders’ equity3.7Fiscal year 2025Cash4.3Shareholders’ equity3.2
FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash n/a n/a 0.2 12.3 3.1 1.1 3.5 4.3
Shareholders’ equity 5.0 5.0 −6.4 −7.9 −3.7 −0.3 3.7 3.2

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
n/a n/a 3.9 3.5 2.5 2.2 5.2 5.1
Growth −10.2% −28.5% −11.6% +133.6% −2.8%
n/a n/a 4.4 4.7 19.8 7.6 7.2 10.4
n/a n/a 1.2 18.7 6.9 5.4 4.7 4.9
−1.0 −3.3 −1.6 −19.9 −24.2 −10.7 −6.7 −10.2
Growth
2.7 −0.5 4.6 n/a n/a n/a n/a n/a
0.6 0.6 0.2 n/a n/a n/a n/a n/a
2.1 −1.1 4.3 −29.1 −24.2 −10.6 −8.0 −10.2
Growth −150.3% −776.1%
Per share
n/a n/a 0.00 −29.64 −139.42 −70.40 −11.45 −3.98
n/a n/a 0.00 −1.48 −139.42 −70.40 −11.45 −3.98
Growth
n/a n/a 15.8 1.0 0.2 0.2 0.7 2.6
n/a n/a 16.5 20.2 0.2 0.2 0.7 2.6
Growth +22.2% −99.1% −16.1% +362.2% +266.6%

† The diluted share count jumps at 2022 and 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 5.2% a year over five years.
  • Operating margin is down 161.1 points on five years ago, at -202.1%.
  • A net loss in 6 of 8 years on file.